A long-term survivor of hilar cholangiocarcinoma with resection of recurrent peritoneal dissemination after R0 surgery: a case report

• Main Authors: Tatsunori Miyata, Hirohisa Okabe, Akira Chikamoto, Takanobu Yamao, Naoki Umezaki, Masayo Tsukamoto, Yuki Kitano, Kota Arima, Shigeki Nakagawa, Katsunori Imai, Daisuke Hashimoto, Yo-ichi Yamashita, Hideo Baba
• Format: Article
• Language: English
• Published: SpringerOpen 2017-10-01
• Series: Surgical Case Reports
• Subjects: Chemotherapy; Hilar cholangiocarcinoma; Long survivor; Recurrence; Peritoneal dissemination
• Online Access: http://link.springer.com/article/10.1186/s40792-017-0386-z

Abstract Background Although hilar cholangiocarcinoma (HCCA) has a very poor prognosis, there are cases in which long-term survival is rarely obtained by multidisciplinary treatment. Case presentation A 61-year-old man diagnosed with HCCA was referred to our hospital. We performed an extended left hemi-hepatectomy and caudate lobectomy with extrahepatic bile duct resection. The tumor stage was T2aN0M0, stage II, based on the TNM classification, seventh edition. R0 resection was successfully performed. Adjuvant chemotherapy was not administered. After 38 months, computed tomography revealed peritoneal dissemination. The patient received chemotherapy with tegafur-gimeracil-oteracil-potassium (S-1) and gemcitabine. The peritoneal dissemination was successfully controlled for more than 50 months. During the treatment, levels of CEA and CA19-9 kept rising slowly, which was followed by bowel obstruction due to peritoneal dissemination of HCCA. The patient underwent resection of transverse colon with tumor nodules, and the tumor was pathologically diagnosed as metastasis of HCCA. Tumor markers decreased to normal levels, and the patient has been free from tumor relapse for 6 months. Conclusions We here report a rare case of HCCA patient with recurrent peritoneal dissemination 3 years after R0 surgery which was sensitive to chemotherapy. The patient successfully received resection of peritoneal dissemination 50 months after the induction of chemotherapy and survived for 10 years.